Примери за използване на Teratogenic risk на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Teratogenic risk.
She understands the teratogenic risk.
Due to the potential teratogenic risk of siponimod women of childbearing potential should.
If both plasma concentrations are below 0.02 mg/l no teratogenic risk is to be expected.
This means that with the help of drugs, teratogenic risk can be reduced to zero and the development of a viral disease prevented.
Several clinical studies have been published during recent years(e.g. Haberman et al 2013)indicating that there is no major teratogenic risk due to the use of atypical antipsychotics.
Odomzo exposes a teratogenic risk to the unborn child.
If a pregnancy is diagnosed or planned, the treatment should be carefully reconsidered andthe patient must be advised of the possible teratogenic risk of cysteamine.
She understands the teratogenic risk to the unborn child.
Therefore, ganciclovir should not be used in pregnant women unless the clinical need for treatment of the woman outweighs the potential teratogenic risk to the foetus.
She understands the expected teratogenic risk to the unborn child.
Due to the potential teratogenic risk arising from unbalanced vitamin A levels, Onpattro should not be used during pregnancy, unless the clinical condition of the woman requires treatment.
She understands the expected teratogenic risk to the unborn child.
O The teratogenic risk of GILENYA: the importance of avoiding pregnancy when undergoing treatment with GILENYA and the need for a negative pregnancy test result prior to treatment initiation.
Data on approximately 2000 exposed pregnancies indicate no increased teratogenic risk associated with the use of inhaled budesonide.
Full patient information about the teratogenic risk and the pregnancy prevention measures should be given by the physician to women of childbearing potential and, as appropriate, to male patients.
Doctors will provide counselling before treatment initiation and regularly thereafter regarding the teratogenic risk of GILENYA and required actions to minimise this risk. .
As there is still a theoretical teratogenic risk connected to rubella containing vaccines it was agreed that this very vulnerable group should not be put at risk. .
If a pregnancy is diagnosed or planned, the treatment should be carefully reconsidered andthe patient must be advised of the possible teratogenic risk of cysteamine(see section 4.6).
As you know, the lack of this element in the mother's body increases teratogenic risk, worsens the predictions of pregnancy and disrupts the development of the baby.
Due to the potential teratogenic risk arising from unbalanced vitamin A levels, inotersen should not be used during pregnancy, unless the clinical condition of the woman requires treatment with inotersen.
If pregnancy does occur during treatment or within four months from stopping treatment,the patient must be advised of the significant teratogenic risk of Rebetol to the foetus(see section 4.4).
There is currently no information to conclude that there is a teratogenic risk following vaccination with MMR vaccines however the theoretical concern remains.
However, given that humans are the most sensitive species to retinoid embryopathy and that several other factors may contribute to an increased systemic exposure, such as excessive use and damaged skin barrier,the PRAC agreed that the teratogenic risk cannot be completely excluded.
Full patient information about the teratogenic risk and the pregnancy prevention measures should be given by the physician to women of childbearing potential and, as appropriate, to male patients.
Doctors will provide counselling before treatment initiation andregularly thereafter regarding the potential teratogenic risk of siponimod and required actions to minimise this risk. .
Full patient information about the teratogenic risk and the strict pregnancy prevention measures as specified in the Pregnancy Prevention Programme should be given by the physician to all patients, both male and female.
Teratogenic risk- CHMP agreed that the risk from the teratogenic potential of Qsiva might be mitigated through the implementation of appropriate risk minimisation measures, which include a Pregnancy Prevention Plan(PPP), the principles of which should be consistent with that agreed across the EU for isotretinoin in 2003.
Full patient information about the teratogenic risk and the pregnancy prevention measures as specified in the Thalidomide Celgene Pregnancy Prevention Programme should be given by the physician to women of childbearing potential and, as appropriate, to male patients.
With regards to the teratogenic risk of topical retinoids(adapalene, alitretinoin, isotretinoin, tretinoin and tazarotene), the PRAC concluded that the data available show that after topical application, systemic exposure is expected to be negligible and unlikely to result in adverse fetal outcomes.